Posted by Michael Wonder on 20 Sep 2024
Dupixent (dupilumab) recommended for EU approval by the CHMP to treat eosinophilic oesophagitis in children as young as 1 year old
20 September 2024 - Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared to placebo, consistent with improvements seen in adults and adolescents.
Regeneron Pharmaceuticals and Sanofi today announced that the EMA’s CHMP adopted a positive opinion recommending the expanded approval of Dupixent (dupilumab) in the European Union for eosinophilic oesophagitis in children down to 1 year of age.
